MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

Search

Intellia Therapeutics Inc

Suletud

SektorTervishoid

27.9 12.73

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.75

Max

28.22

Põhinäitajad

By Trading Economics

Sissetulek

13M

-101M

Müük

-2.4M

14M

Kasumimarginaal

-710.811

Töötajad

403

EBITDA

11M

-108M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+28.53% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. nov 2025

Turustatistika

By TradingEconomics

Turukapital

1.3B

2.6B

Eelmine avamishind

15.17

Eelmine sulgemishind

27.9

Uudiste sentiment

By Acuity

67%

33%

326 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Intellia Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. apr 2025, 09:30 UTC

Peamised uudised

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

Intellia Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

28.53% tõus

12 kuu keskmine prognoos

Keskmine 31.81 USD  28.53%

Kõrge 60 USD

Madal 12 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Intellia Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

17

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

7.24 / 8.43Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

No Evidence

Sentiment

By Acuity

326 / 371 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat